☆ 4.2 Article

Patient Preferences in the Management of Hidradenitis Suppurativa: Results of a Multinational Discrete Choice Experiment in Europe

PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2023)

Related references

Note: Only part of the references are listed.

Article Dermatology

Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment

Marco Boeri et al.

Summary: This study identified the important attributes for systemic atopic dermatitis treatments through qualitative interviews and an online survey. The findings showed that patients prioritize attributes such as safety risks, efficacy, and mode of administration.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

Add to Collection

Article Dermatology

Incidence and remission rates of self-reported hidradenitis suppurativa - A prospective cohort study conducted in Danish blood donors

R. Kjaersgaard Andersen et al.

Summary: The incidence and remission rates of self-reported HS are high, with factors such as gender, smoking, and BMI affecting both the development and recovery of HS. Females with BMI above 25, active smokers, and individuals with symptoms in multiple areas are more likely to develop self-reported HS, while weight loss and smoking cessation can significantly impact the remission rate.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Add to Collection

Article Health Care Sciences & Services

Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study

Krisztian Gaspar et al.

Summary: This study assessed the cost-of-illness of HS from a societal perspective in Hungary and found that HS imposes a substantial burden on patients and society, predominantly arising from productivity loss and biological therapy. Factors such as disease severity, male sex, and coexisting inflammatory bowel disease may lead to higher direct medical costs, while lower education level and worse quality-of-life outcomes predicted higher indirect costs.

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2022)

Add to Collection

Review Biochemistry & Molecular Biology

New and Emerging Targeted Therapies for Hidradenitis Suppurativa

Adela Markota Cagalj et al.

Summary: This review examines the evidence for emerging therapies targeting the main pro-inflammatory cytokines in Hidradenitis suppurativa (HS). The most promising biologics in phase III trials are anti-IL-17 antibodies, secukinumab, and bimekizumab. An anti-IL-1 biologic, bermekimab, is currently in phase II trials and shows encouraging results. However, the clinical efficacies of all new targeted therapies published up to this point are limited, and more studies are needed to evaluate the efficacy of biological therapies for HS.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Dermatology

Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US

J. R. Ingram et al.

Summary: This study investigated the clinical unmet needs of patients with Hidradenitis suppurativa from the perspectives of physicians and patients. Despite receiving treatment, patients still experienced a high disease burden with significant impact on their quality of life.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Add to Collection

Article Rheumatology

Preferences for Biologic Treatment in Patients With Psoriatic Arthritis: A Discrete Choice Experiment

Daniel Sumpton et al.

Summary: In this study, it was found that patients with psoriatic arthritis preferred oral biologic medications, prioritizing the avoidance of severe complications, maintaining the ability to work and engage in normal activities, and avoiding infection over clinical efficacy measures.

ARTHRITIS CARE & RESEARCH (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Biologics and Small Molecule Inhibitors for Treating Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis

Chun-Hsien Huang et al.

Summary: The study found that adalimumab and bimekizumab are the only two biologics effective and with an acceptable safety profile in treating moderate-to-severe hidradenitis suppurativa (HS). Adalimumab also showed superiority in improving the dermatology life quality index of patients.

BIOMEDICINES (2022)

Add to Collection

Article Dermatology

Biologic use in hidradenitis suppurativa: patient perspectives and barriers

Devea R. De et al.

Summary: This study aimed to explore the perspectives and barriers of Hidradenitis suppurativa (HS) patients on biologics. The survey results revealed that fear of side effects, high cost/lack of insurance coverage, and frequency of weekly injections were the main barriers to using biologics. It was also found that patients whose primary healthcare provider was a non-dermatologist and who were not seen at an HS specialty clinic were less knowledgeable about how biologics work.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

Add to Collection

Article Dermatology

Interviewing Women with Hidradenitis Suppurativa-Thematic and Content Analysis

Shani Fisher et al.

Summary: This study investigated the impact of HS on women's self-perception and life experiences. The results revealed negative effects of HS on various aspects such as physical, emotional, coping, and functional aspects, including pain, shame, loss of femininity, and intimacy. However, women also showed strength and optimism.

ADVANCES IN SKIN & WOUND CARE (2022)

Add to Collection

Article Health Care Sciences & Services

Identifying Unmet Care Needs and Important Treatment Attributes in the Management of Hidradenitis Suppurativa: A Qualitative Interview Study

Damon Willems et al.

Summary: HS is an inflammatory skin disease that significantly impacts patients' quality of life. This research conducted interviews with both patients and healthcare professionals to understand unmet needs and treatment considerations. Both patients and HCPs identified lacking quality-of-life improvement, low treatment effectiveness, inadequate pain control, low disease awareness, and delayed diagnosis as common unmet needs. Patients emphasized pain management and access to specialists, while both patients and HCPs prioritized treatment attributes related to effectiveness.

PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2022)

Add to Collection

Article Dermatology

The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study

Kelsey R. van Straalen et al.

Summary: The study demonstrated significant efficacy of both oral tetracycline treatment and clindamycin plus rifampicin combination therapy for patients with hidradenitis suppurativa after 12 weeks. There were no significant differences in efficacy between the two treatments, regardless of disease severity.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study

L. M. Prens et al.

Summary: This study evaluated the drug survival of antitumour necrosis factor biologics for patients with hidradenitis suppurativa in daily practice. Survival rates for adalimumab and infliximab were similar at 12 months, mainly determined by ineffectiveness. Age, disease duration (adalimumab), and surgery (infliximab) were identified as predictors for longer drug survival.

BRITISH JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Article Health Care Sciences & Services

The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa

Alex Bato et al.

Summary: The study aimed to compare the measurement properties of two adult versions of EQ-5D in patients with Hidradenitis suppurativa (HS), with EQ-5D-5L outperforming EQ-5D-3L in terms of feasibility, informativity, and validity for important clinical characteristics. EQ-5D-5L was recommended for assessing HS patients across various settings.

QUALITY OF LIFE RESEARCH (2021)

Add to Collection

Review Medicine, General & Internal

Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review

Paul M. Overton et al.

Summary: Patients with chronic immune system disorders tend to prefer subcutaneous over intravenous administration; patient experience has a significant impact on preferences; those preferring subcutaneous administration tend to prefer home treatment, while those preferring intravenous infusion tend to prefer hospital treatment.

PATIENT PREFERENCE AND ADHERENCE (2021)

Add to Collection

Review Pharmacology & Pharmacy

Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa

Pim Aarts et al.

Summary: Hidradenitis suppurativa is a chronic autoimmune skin disease characterized by inflammatory nodules and abscesses due to the upregulation of various immune cells and pro-inflammatory cytokines. While adalimumab is currently the only approved drug for HS, other biologics and small molecules targeting different inflammatory pathways are being researched and utilized.

DRUGS (2021)

Add to Collection

Article Dermatology

Target molecules for future hidradenitis suppurativa treatment

Christos C. Zouboulis et al.

Summary: The registration of adalimumab in 2015 marked a significant advancement in the treatment of HS, but its effectiveness in clinical practice is variable. Promising novel therapeutic targets for HS, such as IL-17 biologics and spesolimab targeting IL-36, are currently under investigation.

EXPERIMENTAL DERMATOLOGY (2021)

Add to Collection

Review Environmental Sciences

The Burden of Hidradenitis Suppurativa Signs and Symptoms in Quality of Life: Systematic Review and Meta-Analysis

Trinidad Montero-Vilchez et al.

Summary: This study summarized the scientific evidence regarding the impact of signs and symptoms in HS patients on QoL, finding a strong correlation between the intensity of pain, itching, malodor, suppuration, and the overall QoL or specific QoL dimensions such as sexual distress, anxiety, depression, and sleep. Assessment of these symptoms should be thorough and included in the routine evaluation of HS patients to motivate treatment modifications and improve patient health.

INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2021)

Add to Collection

Article Dermatology

Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial

Sophie Glatt et al.

Summary: In this study, bimekizumab showed clinically meaningful improvements in patients with moderate to severe HS, demonstrating greater efficacy compared to placebo. The safety profile of bimekizumab was consistent with previous studies, supporting further evaluation for HS treatment.

JAMA DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project

Amit Garg et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection

Article Dermatology

The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials

J. S. Kirby et al.

BRITISH JOURNAL OF DERMATOLOGY (2020)

Add to Collection

Article Dermatology

High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa

Mondana H. Ghias et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)

Add to Collection

Article Dermatology

Epidemiology of hidradenitis suppurativa in Germany - an observational cohort study based on a multisource approach

N. Kirsten et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

Add to Collection

Review Medicine, General & Internal

The importance of understanding patient and physician preferences for psoriasis treatment characteristics: a systematic review of discrete-choice experiments

Noem Sain et al.

CURRENT MEDICAL RESEARCH AND OPINION (2020)

Add to Collection

Article Dermatology

Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System

Georgios Kokolakis et al.

DERMATOLOGY (2020)

Add to Collection

Article Economics

Early health economic modelling for a treatment candidate in hidradenitis suppurativa

Damon Willems et al.

JOURNAL OF MEDICAL ECONOMICS (2020)

Add to Collection

Article Health Care Sciences & Services

Use of Patient Preference Studies in HTA Decision Making: A NICE Perspective

Jacoline C. Bouvy et al.

PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2020)

Add to Collection

Article Dermatology

Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study

Christos C. Zouboulis et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)

Add to Collection

Article Multidisciplinary Sciences

Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data

Luca Quartuccio et al.

JOURNAL OF ADVANCED RESEARCH (2019)

Add to Collection

Review Economics

Using Latent Class Analysis to Model Preference Heterogeneity in Health: A Systematic Review

Mo Zhou et al.

PHARMACOECONOMICS (2018)

Add to Collection

Article Dermatology

A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process

L. Thorlacius et al.

BRITISH JOURNAL OF DERMATOLOGY (2018)

Add to Collection

Article Economics

Assessing Rationality in Discrete Choice Experiments in Health: An Investigation into the Use of Dominance Tests

Tommi Tervonen et al.

VALUE IN HEALTH (2018)

Add to Collection

Article Dermatology

Nonadherence to psoriasis medication as an outcome of limited coping resources and conflicting goals: findings from a qualitative interview study with people with psoriasis

R. J. Thorneloe et al.

BRITISH JOURNAL OF DERMATOLOGY (2017)

Add to Collection

Review Health Care Sciences & Services

The Role of Qualitative Research Methods in Discrete Choice Experiments: A Systematic Review and Survey of Authors

Caroline Vass et al.

MEDICAL DECISION MAKING (2017)

Add to Collection

Review Health Care Sciences & Services

Improving the quality of discrete-choice experiments in health: how can we assess validity and reliability?

Ellen M. Janssen et al.

EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2017)

Add to Collection

Article Dermatology

Disutility in Patients with Hidradenitis Suppurativa: A Cross-sectional Study Using EuroQoL-5D

Peter Theut Riis et al.

ACTA DERMATO-VENEREOLOGICA (2016)

Add to Collection

Article Medicine, General & Internal

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa

Alexa B. Kimball et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Economics

Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force

A. Brett Hauber et al.

VALUE IN HEALTH (2016)

Add to Collection

Letter Dermatology

Diagnostic delay in hidradenitis suppurativa is a global problem

D. M. Saunte et al.

BRITISH JOURNAL OF DERMATOLOGY (2015)

Add to Collection

Article Dermatology

Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation

Christos C. Zouboulis et al.

DERMATOLOGY (2015)

Add to Collection

Article Dermatology

European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa

C. C. Zouboulis et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2015)

Add to Collection

Article Surgery

Incorporating patient-preference evidence into regulatory decision making

Martin P. Ho et al.

SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES (2015)

Add to Collection

Article Health Care Sciences & Services

Sample Size Requirements for Discrete-Choice Experiments in Healthcare: a Practical Guide

Esther W. de Bekker-Grob et al.

PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2015)

Add to Collection

Article Economics

Chronic pain patients' treatment preferences: a discrete-choice experiment

Axel C. Muehlbacher et al.

EUROPEAN JOURNAL OF HEALTH ECONOMICS (2015)

Add to Collection

Article Orthopedics

Patient preferences for adherence to treatment for osteoarthritis: the MEdication Decisions in Osteoarthritis Study (MEDOS)

Tracey-Lea Laba et al.

BMC MUSCULOSKELETAL DISORDERS (2013)

Add to Collection

Article Dermatology

Patient preferences for psoriasis treatments: impact of treatment experience

M. -L. Schaarschmidt et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)

Add to Collection

Article Dermatology

Matching physicians' treatment recommendations to patients' treatment preferences is associated with improvement in treatment satisfaction

N. Umar et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)

Add to Collection

Article Economics

Constructing Experimental Designs for Discrete-Choice Experiments: Report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force

F. Reed Johnson et al.

VALUE IN HEALTH (2013)

Add to Collection

Article Medicine, General & Internal

Hidradenitis Suppurativa

Gregor B. E. Jemec

NEW ENGLAND JOURNAL OF MEDICINE (2012)

Add to Collection

Article Economics

Conjoint Analysis Applications in Health-a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force

John F. P. Bridges et al.

VALUE IN HEALTH (2011)

Add to Collection

Review Economics

Conducting discrete choice experiments to inform Healthcare decision making

Emily Lancsar et al.

PHARMACOECONOMICS (2008)

Add to Collection

Article Rheumatology

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy - Results from the British Society for Rheumatology Biologics Register

W. G. Dixon et al.

ARTHRITIS AND RHEUMATISM (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.